Spots Global Cancer Trial Database for hnscc
Every month we try and update this database with for hnscc cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 | NCT04534205 | Unresectable He... Metastatic Head... Recurrent Head ... | BNT113 Pembrolizumab | 18 Years - | BioNTech SE | |
| Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) | NCT04675294 | Head and Neck C... Head and Neck S... | evorpacept pembrolizumab | 18 Years - | ALX Oncology Inc. | |
| PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC | NCT02544880 | Head and Neck S... Head and Neck C... | Tadalafil Anti-MUC1 Vacci... Anti-Influenza ... Tadalafil Place... Anti-MUC1 Vacci... Standard of Car... Anti-Influenza ... | 18 Years - | University of Miami | |
| Towards A Better Paradigm for Head and Neck Cancer Treatment Applying Artificial Intelligence. HNC-TACTIC. | NCT05117775 | Head and Neck C... | No intervention... | 18 Years - | Savana Research | |
| Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy | NCT03719690 | HRAS Gene Mutat... HNSCC | Tipifarnib HRAS Detection ... | 18 Years - | Kura Oncology, Inc. | |
| Amifostine With IMRT for Submandibular and Sublingual Salivary Sparing During Head and Neck Cancer Treatment | NCT00409331 | Head and Neck C... | Amifostine Intensity- Modu... | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours | NCT05605522 | Pancreatic Duct... Squamous Cell C... Colorectal Canc... Gastric Cancer Ewing Sarcoma NTSR1 Expressin... Neuroendocrine ... | [225]-FPI-2059 [111In]-FPI-205... | 18 Years - | Fusion Pharmaceuticals Inc. | |
| Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients | NCT03916627 | Non-small Cell ... Hepatocellular ... Head and Neck S... | cemiplimab Platinum Double... fianlimab | 18 Years - | Regeneron Pharmaceuticals | |
| Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1. | NCT03666273 | Advanced Solid ... Head and Neck S... | Bapotulimab (BA... Bapotulimab (BA... | 18 Years - | Bayer | |
| Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma | NCT03336606 | Head and Neck C... Head and Neck S... Melanoma Cell Cancer, Sq... Carcinoma, Squa... | MEDI0562 | 18 Years - | Providence Health & Services | |
| A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma | NCT06256588 | Neoplasms, Head... | Dostarlimab Placebo | 18 Years - | GlaxoSmithKline | |
| Study of Circulating Tumor DNA (ctDNA) Kinetics in Immuno-oncology (IO-KIN) | NCT04606940 | Head and Neck C... Advanced Cancer Metastatic Canc... HNSCC Squamous Cell C... | 18 Years - | University Health Network, Toronto | ||
| Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH) | NCT02999087 | HNSCC | Cetuximab avelumab Cisplatin IMRT | 18 Years - 80 Years | Groupe Oncologie Radiotherapie Tete et Cou | |
| Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies | NCT04541108 | Solid Tumor | Rilvegostomig Volrustomig Sabestomig Pembrolizumab | 18 Years - | Presage Biosciences | |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
| Association Between Tinnitus and Hearing Loss in Locally Advanced Head and Neck Cancer Treated by Radiotherapy Alone or With Chemotherapy: a Prospective and Multicenter Study | NCT05946577 | Head Cancer Neck Cancer | 18 Years - | Assistance Publique - Hôpitaux de Paris | ||
| Cetuximab IRDye800 Study as an Optical Imaging Agent to Detect Cancer During Surgical Procedures | NCT01987375 | Head and Neck C... | Cetuximab-IRDye... | 19 Years - | Stanford University | |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | NCT05581004 | Locally Advance... NSCLC HNSCC Melanoma TNBC Esophageal Canc... Gastric Cancer Cervical Cancer Urothelial Carc... Clear Cell RCC HCC | RO7502175 Atezolizumab | 18 Years - | Genentech, Inc. | |
| NBTXR3 With or Without Cetuximab in LA-HNSCC | NCT04892173 | Locally Advance... Aged | NBTXR3 Cetuximab Radiation Thera... | 65 Years - | Nanobiotix | |
| Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia | NCT04534127 | Skin Cancer Mucosal Neoplas... Soft Tissue Neo... | Radiation: Diff... | 18 Years - | Alpha Tau Medical LTD. | |
| MRI - Guided Adaptive RadioTHerapy for Dysphagia in Head and Neck Cancer | NCT05831917 | HNSCC | Radiotherapy | 18 Years - 70 Years | Sichuan Cancer Hospital and Research Institute | |
| First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors | NCT04417465 | Advanced Solid ... | ABBV-CLS-579 PD-1 inhibitor VEGFR TKI | 18 Years - | Calico Life Sciences LLC | |
| Human Papillomavirus (HPV) Oral Transmission Study in Partners Over Time | NCT01342978 | Oropharyngeal C... Human Papilloma... | 18 Years - | Johns Hopkins Bloomberg School of Public Health | ||
| Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced HNSCC | NCT02999646 | Head and Neck S... | MVX-ONCO-1 | 18 Years - | Maxivax SA | |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
| A Safety and Efficacy Study for Combinational Treatment of DaRT and Check Point Inhibitor for Recurrent Unresectable or mHNSCC | NCT05047094 | Head and Neck S... Skin Cancer Metastatic Head... | Diffusing Alpha... Pembrolizumab | 18 Years - | Alpha Tau Medical LTD. | |
| Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma | NCT03422536 | Head and Neck B... Recurrent Head ... Recurrent Oroph... Squamous Cell C... Stage IV Squamo... Stage IV Squamo... Stage IV Nasoph... Stage IV Oropha... Stage IVA Lip a... Stage IVA Nasal... Stage IVA Nasop... Stage IVA Oroph... Stage IVB Lip a... Stage IVB Nasal... Stage IVB Nasop... Stage IVB Oroph... Stage IVC Lip a... Stage IVC Nasal... Stage IVC Nasop... Stage IVC Oroph... Head and Neck C... Oropharyngeal C... HNSCC Stage IV Lip an... | Cetuximab Ficlatuzumab | 18 Years - | University of Arizona | |
| FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER) | NCT05432193 | Pancreatic Duct... Colorectal Canc... Esophageal Canc... Melanoma (Skin) Soft Tissue Sar... Head and Neck S... Cholangiocarcin... | [Ga-68]-PNT6555 [Lu-177]-PNT655... | 18 Years - | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | |
| Prospective Study for the Prognostic and Predictive Role of Circulating Tumor Cells in Patients With Oropharyngeal Squamous Cell Carcinoma: CTCO (Circulating Tumor Cells in the Oropharynx) | NCT04696744 | Circulating Tum... Oropharyngeal C... | CTC detection | 18 Years - | Hospices Civils de Lyon | |
| Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC | NCT05814666 | HNSCC | Danvatirsen Pembrolizumab | 18 Years - | Flamingo Therapeutics NV | |
| Retreatment With Intratumoral Diffusing Alpha Radiation Emitters | NCT04540588 | Skin Cancer Mucosal Neoplas... Soft Tissue Neo... | Radiation: Diff... | 18 Years - | Alpha Tau Medical LTD. | |
| A Biomarker-driven, Open Label, Single Arm, Multicentre Phase II Study of Abemaciclib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Who Failed to Platinum-based Therapy | NCT03356587 | HNSCC Head and Neck N... | Abemaciclib | 20 Years - | Seoul National University Hospital | |
| Study of 3-Dimensional Conformal Radiotherapy (3D-CRT) Versus Intensity Modulated Radiotherapy (IMRT) for Head and Neck Squamous Cell Carcinoma (HNSCC) | NCT00652613 | Squamous Cell C... | 3 Dimensional R... Intensity Modul... | 18 Years - 65 Years | Tata Memorial Hospital | |
| The Head and Neck Tumor Biobank | NCT01644786 | Head and Neck S... | 18 Years - | Maastricht Radiation Oncology | ||
| A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers | NCT05544929 | Carcinoma, Non-... Cutaneous Melan... Carcinoma, Rena... Carcinoma, Ovar... Nasopharyngeal ... Carcinoma, Thym... Anal Cancer Mesothelioma Esophagogastric... High Microsatel... Squamous Cell C... Triple Negative... | KFA115 pembrolizumab | 18 Years - | Novartis | |
| Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma | NCT00911326 | Head and Neck S... | Lymphoseek | 18 Years - | Navidea Biopharmaceuticals | |
| A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC | NCT05054439 | Head and Neck S... | SI-B001 Paclitaxel | 18 Years - | Sichuan Baili Pharmaceutical Co., Ltd. | |
| Chemo-radiotherapy Versus Radiotherapy in the Treatment of Salivary Glands and Nasal Tumors (IMRT or Protontherapy) | NCT02998385 | HNSCC | Cisplatin radiotherapy | 18 Years - | Groupe Oncologie Radiotherapie Tete et Cou | |
| Pemetrexed (Alimta) in Patients With Head and Neck Squamous Cell Cancer | NCT00507858 | Head and Neck C... | Pemetrexed Dexamethasone | 18 Years - | M.D. Anderson Cancer Center | |
| Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | NCT01836029 | Carcinoma, Squa... | VTX-2337 Carboplatin Cisplatin 5-fluorouracil Placebo | 18 Years - | Celgene | |
| Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer | NCT03107182 | HPV-Related Squ... HNSCC | nab-paclitaxel Carboplatin Nivolumab Cisplatin Hydroxyurea 5-FU Dexamethasone Famotidine Diphenhydramine Paclitaxel Transoral robot... Adjuvant RT Chemoradiothera... | 18 Years - | University of Chicago | |
| Evaluation of 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Cancer. | NCT01124409 | HEAD AND NECK C... CARCINOMA OROPH... CARCINOMA PYRIF... CARCINOMA LARYN... | EPID Verificati... CBCT verificati... | 18 Years - 65 Years | All India Institute of Medical Sciences, New Delhi | |
| A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors | NCT05537740 | Advanced Solid ... | BAY3375968 Pembrolizumab | 18 Years - | Bayer | |
| Phase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck Cancer | NCT02308072 | Head and Neck C... | Olaparib Cisplatin IMRT | 18 Years - | University College, London | |
| A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours | NCT06147037 | Advanced Solid ... Metastatic Colo... Head and Neck S... Non-small Cell ... Pancreatic Duct... | FPI-2053 [111In]-FPI-210... [225Ac]-FPI-206... | 18 Years - | Fusion Pharmaceuticals Inc. | |
| A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 | NCT06003231 | Carcinoma, Squa... Carcinoma, Non-... Ovarian Neoplas... Endometrial Neo... | disitamab vedot... | 18 Years - | Seagen Inc. | |
| A Biomarker-driven, Open Label, Single Arm, Multicentre Phase II Study of Abemaciclib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Who Failed to Platinum-based Therapy | NCT03356587 | HNSCC Head and Neck N... | Abemaciclib | 20 Years - | Seoul National University Hospital | |
| Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC) | NCT04938609 | Head and Neck C... Head and Neck S... | Pembrolizumab Stereotactic Bo... Surgical Resect... | 18 Years - | Providence Health & Services | |
| Nimotuzumab Combined With Radiotherapy in High-risk Patients With HNSCC Not Suitable for Cisplatin After Surgery | NCT05024019 | Head and Neck S... | Nimotuzumab | 18 Years - | Eye & ENT Hospital of Fudan University | |
| Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma | NCT03336606 | Head and Neck C... Head and Neck S... Melanoma Cell Cancer, Sq... Carcinoma, Squa... | MEDI0562 | 18 Years - | Providence Health & Services | |
| A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | NCT04032704 | Small Cell Lung... Non-small Cell ... Non-small Cell ... Head and Neck S... Esophageal Squa... Gastric Adenoca... Gastroesophagea... Prostate Cancer Melanoma | ladiratuzumab v... pembrolizumab | 18 Years - | Seagen Inc. | |
| Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy | NCT05337631 | HNSCC Oral Cavity Can... Oropharynx Canc... Hypopharynx Can... Larynx Cancer | 65 Years - | University Hospital Freiburg | ||
| A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | NCT04032704 | Small Cell Lung... Non-small Cell ... Non-small Cell ... Head and Neck S... Esophageal Squa... Gastric Adenoca... Gastroesophagea... Prostate Cancer Melanoma | ladiratuzumab v... pembrolizumab | 18 Years - | Seagen Inc. | |
| Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | NCT04114136 | Melanoma NSCLC Hepatocellular ... Urothelial Canc... Gastric Adenoca... HNSCC Esophageal Aden... Microsatellite ... | Nivolumab or Pe... Metformin Rosiglitazone | 18 Years - | University of Pittsburgh | |
| Ferumoxytol - Iron Oxide Nanoparticle Magnetic Resonance Dynamic Contrast Enhanced MRI | NCT01895829 | Head and Neck C... | Magnetic Resona... Ferumoxytol | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of DB-1310 in Advanced/Metastatic Solid Tumors | NCT05785741 | Advanced Solid ... | DB-1310 | 18 Years - | DualityBio Inc. | |
| Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC) | NCT04831450 | Head and Neck S... HNSCC Squamous Cell C... Squamous Cell C... Squamous Cell C... | Cemiplimab-Rwlc | 18 Years - | University of Miami | |
| Efficacy Study of Temsirolimus to Treat Head and Neck Cancer | NCT01172769 | Head and Neck S... | Temsirolimus | 18 Years - | Hannover Medical School | |
| Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux | NCT00609284 | HNSCC | cetuximab Carboplatin, 5F... Radiotherapy | 18 Years - 70 Years | Groupe Oncologie Radiotherapie Tete et Cou | |
| A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors | NCT06158958 | Solid Tumors | ABBV-303 Budigalimab | 18 Years - | AbbVie | |
| Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer | NCT05877430 | NSCLC HNSCC Melanoma Metastatic Canc... Advanced Solid ... Advanced Cancer | CJRB-101 Pembrolizumab i... | 18 Years - | CJ Bioscience, Inc. | |
| INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC | NCT06295731 | Head and Neck S... | INBRX-106 Pembrolizumab | 18 Years - | Inhibrx, Inc. | |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | NCT05581004 | Locally Advance... NSCLC HNSCC Melanoma TNBC Esophageal Canc... Gastric Cancer Cervical Cancer Urothelial Carc... Clear Cell RCC HCC | RO7502175 Atezolizumab | 18 Years - | Genentech, Inc. | |
| Prospective Study for the Prognostic and Predictive Role of Circulating Tumor Cells in Patients With Oropharyngeal Squamous Cell Carcinoma: CTCO (Circulating Tumor Cells in the Oropharynx) | NCT04696744 | Circulating Tum... Oropharyngeal C... | CTC detection | 18 Years - | Hospices Civils de Lyon | |
| A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | NCT04254107 | Non-small Cell ... Gastric Carcino... Gastroesophagea... Classical Hodgk... Diffuse Large B... Peripheral T-ce... Cutaneous Melan... Head and Neck S... Bladder Cancer Ovarian Cancer Triple Negative... Cervical Cancer | SEA-TGT sasanlimab brentuximab ved... | 18 Years - | Seagen Inc. | |
| Phase II Trial of Carboplatin, 5-FU and Cetuximab in Elderly Fit (no Frailty) Patients With Recurrent/Metastatic HNSCC | NCT01864772 | Metastatic or R... | Carbo, 5FU, Cet... | 70 Years - | Groupe Oncologie Radiotherapie Tete et Cou | |
| Real-world Analysis on the Efficacy and Safety of Neoadjuvant Therapy for Head and Neck Squamous Cell Carcinoma （neoHNSCC） | NCT06011993 | Head and Neck S... | 18 Years - 80 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | ||
| Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma | NCT05980000 | Recurrent Head ... Recurrent Head ... Recurrent Head ... Metastatic Head... Metastatic Head... HNSCC | Ramucirumab Pembrolizumab | 18 Years - | Washington University School of Medicine | |
| A Study of SGN-PDL1V in Advanced Solid Tumors | NCT05208762 | Carcinoma, Non-... Squamous Cell C... Esophageal Squa... Ovarian Neoplas... Melanoma Triple Negative... Gastric Cancer | SGN-PDL1V pembrolizumab | 18 Years - | Seagen Inc. | |
| Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia. | NCT03889899 | Skin Cancer Mucosal Neoplas... Soft Tissue Neo... | Radiation: Diff... | 18 Years - | Alpha Tau Medical LTD. | |
| Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | NCT04114136 | Melanoma NSCLC Hepatocellular ... Urothelial Canc... Gastric Adenoca... HNSCC Esophageal Aden... Microsatellite ... | Nivolumab or Pe... Metformin Rosiglitazone | 18 Years - | University of Pittsburgh | |
| Phase II Trial of Carboplatin, 5-FU and Cetuximab in Elderly Fit (no Frailty) Patients With Recurrent/Metastatic HNSCC | NCT01864772 | Metastatic or R... | Carbo, 5FU, Cet... | 70 Years - | Groupe Oncologie Radiotherapie Tete et Cou | |
| Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma | NCT01154920 | Head and Neck S... | Paclitaxel Carboplatin Cetuximab Docetaxel Cisplatin Fluorouracil Radiotherapy (R... Chemotherapy | 18 Years - | M.D. Anderson Cancer Center | |
| ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer | NCT05182866 | Head and Neck C... Squamous Cell C... | ASP-1929 Photoi... | 18 Years - | Rakuten Medical, Inc. | |
| PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, and Sabestomig in HNSCC | NCT06366451 | Head and Neck S... | Rilvegostomig Volrustomig Sabestomig Pembrolizumab | 18 Years - | Presage Biosciences | |
| Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas | NCT02503423 | Solid Tumors Lymphoma | ASTX660 | 18 Years - | Astex Pharmaceuticals, Inc. | |
| Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Squamous Cell Carcinoma | NCT06190275 | HNSCC Adults | GT201 in combin... | 18 Years - 70 Years | Grit Biotechnology | |
| Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma | NCT04861467 | HNSCC | Camrelizumab | 18 Years - 70 Years | ChineseAMS | |
| A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study | NCT02841748 | Head and Neck C... Squamous Cell C... | Pembrolizumab Placebo | 18 Years - | University of Chicago | |
| A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC) | NCT06163534 | Head and Neck S... | 18 Years - | Tempus AI |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
